Marqeta Inc vs ResMed Inc. — how do they compare? Marqeta Inc trades at $17.21 (market cap $1.85B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 15.6× Marqeta Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | RMD | |
|---|---|---|
Market Cap | $1.85B | $28.81B |
Sector | Technology | Health |
52-Week High | $27.32 | $293.73 |
52-Week Low | $15.04 | $182.82 |
Enterprise Value | $1.15B | $27.99B |
Dividend Yield | — | 1.21% |
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.44, down slightly by 0.29% today. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent financials reveal revenue growth to $624.88M in 2025, but profitability remains weak with a net margin of -2.23%. The company's expansion into Europe with Expensify and a recent 4:1 reverse stock split are key developments. Analyst consensus is a 'Buy' with a $19.00 price target, indicating modest upside potential.
MQ presents a cautious opportunity with growth initiatives offset by profitability challenges. The stock's high P/E of 439 reflects investor optimism on future earnings, but thin margins and inconsistent quarterly results pose risks. Upside depends on successful execution of European expansion and sustained revenue growth, while downside risks include competitive pressures and failure to achieve profitability. Institutional sentiment is mixed, with 59% of analysts recommending 'Hold'.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →